Rare diseases
Investigational molecules
Locations
Block C 77 Sir John Rogerson’s Quay, Grand Canal Docklands, D02 VK60 Dublin, Ireland
Prothena Biosciences Limited focuses its clinical research on light chain (AL) amyloidosis, with particular attention to advanced systemic amyloidosis affecting patients with severe disease burden. The sponsor’s work in this area centers on cardiac involvement and outcomes linked to all-cause mortality.
The research activity reflects interest in therapies used alongside standard of care for patients with advanced plasma cell dyscrasia-related amyloidosis.
Prothena Biosciences Limited runs clinical trials in conditions such as Primary amyloidosis, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
